Karen A. Cashmere - 11 Jul 2025 Form 4 Insider Report for ZyVersa Therapeutics, Inc. (ZVSA)

Role
Chief Commercial Officer
Signature
/s/ Stephen C. Glover as Attorney-in-Fact for Karen A. Cashmere pursuant to Power of Attorney
Issuer symbol
ZVSA
Transactions as of
11 Jul 2025
Net transactions value
$0
Form type
4
Filing time
16 Jul 2025, 12:55:04 UTC
Previous filing
18 Jul 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cashmere Karen A. Chief Commercial Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, SUITE 208, WESTON /s/ Stephen C. Glover as Attorney-in-Fact for Karen A. Cashmere pursuant to Power of Attorney 16 Jul 2025 0001954546

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZVSA Stock Options Award $0 +48,100 $0.000000 48,100 11 Jul 2025 Common Stock 48,100 $0.5900 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4 is being filed late as the result of an inadvertent administrative oversight.
F2 The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.